Enliven Therapeutics Shares Important Insights on ELVN-001 Data Update
BOULDER, Colo. — Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biotech company focused on precision oncology, is pleased to announce significant details about the updated Phase 1a data for ELVN-001. This data will be featured in an oral presentation at the prestigious European Society of Hematology International Chronic Myeloid Leukemia Foundation (ESH-iCMLf) 26th Annual John Goldman Conference, happening from September 27 to 29 in Prague.
What is ELVN-001?
ELVN-001 is a targeted small molecule kinase inhibitor specifically designed to inhibit the BCR-ABL gene fusion, which acts as the oncogenic driver in chronic myeloid leukemia (CML) patients. This cutting-edge therapy seeks to provide renewed hope in managing this challenging illness.
Details of the Presentation
The oral presentation’s specifics are vital for anyone keen on the latest developments in CML treatments. Here are the key details you should be aware of:
Presentation Overview
Title: Preliminary Safety and Efficacy of ELVN-001, a Selective Active Site Inhibitor of BCR::ABL1 in CML
Presenter: Fabian Lang, MD, from Goethe University Hospital
Session: Scientific Session 5: New Drugs and Combinations
Date/Time: Saturday, September 28, 3:00 - 4:20 p.m. CEST
Presentation Slot: 3:35 - 3:50 p.m. CEST / 9:35 - 9:50 a.m. ET
How to Access Presentation Materials
Once the presentation concludes, attendees can find a copy of the materials by visiting the Company’s website in the “Program Presentations & Publications” section. This commitment to transparency ensures that everyone interested can stay updated on the findings and advancements regarding ELVN-001.
About Enliven Therapeutics
Enliven Therapeutics is dedicated to improving the lives of cancer patients through the discovery and development of small molecule inhibitors. The goal isn’t just to prolong life but to enhance the quality of life for those facing significant health challenges. With a strong approach to precision oncology, Enliven is focused on both current and future needs, driving the development of potential first-in-class or best-in-class therapies.
Open Communication
For further inquiries, investors and media representatives are encouraged to reach out directly to the Company. Enliven emphasizes the importance of maintaining open communication channels.
Contact Information
Investors can connect by email at ir@enliventherapeutics.com.
Media inquiries can be directed to media@enliventherapeutics.com.
Frequently Asked Questions
What is the purpose of ELVN-001?
ELVN-001 aims to selectively target the BCR-ABL gene fusion, which is a key factor in chronic myeloid leukemia (CML).
Where will the updated Phase 1a data be presented?
The data will be presented at the ESH-iCMLf 26th Annual John Goldman Conference in Prague.
When is the scheduled time for the presentation?
The presentation is set for September 28, in the 3:35 - 3:50 p.m. CEST timeslot.
How can I obtain the presentation materials?
Materials will be accessible on Enliven’s website under the “Program Presentations & Publications” section after the presentation concludes.
How does Enliven Therapeutics assist cancer patients?
Enliven focuses on enhancing patient outcomes through innovative therapies that improve both survival rates and quality of life for those battling cancer.
